He grows cancer-killing immune cells in a tank. No donor, no waiting list, no two patients getting a different batch.
Founder, President & CEO · HebeCell Corp · Natick, MA
JOHN LU · THE PLATFORM GUY
A natural killer cell is the immune system's first responder - it finds a tumor cell and dismantles it without being told who the enemy is. The trouble has always been supply. Pull NK cells from a donor and you get a finite, variable batch; the next patient gets something slightly different. John Lu's answer was to stop harvesting and start manufacturing. At HebeCell, the company he founded in 2016, NK cells are coaxed out of pluripotent stem cells and grown in 3D suspension inside single-use bioreactors - feeder-free, reproducible, and in principle endless. The company's claim is blunt: no other lab can make NK cells this way, indefinitely, from stem cells.
His conference talk was titled "One platform, endless pipelines." It is also the entire business plan: build the manufacturing process once, then aim it at any disease that immune cells can reach.
The platform is called ProtoNK. It starts with induced pluripotent stem cells - ordinary cells reprogrammed back to a blank, self-renewing state - and differentiates them into natural killer cells. The unusual part is the geometry. Instead of the flat, two-dimensional culture plates and feeder layers most groups rely on, HebeCell grows its cells as 3D spheroids floating in liquid, designed from the start for single-use bioreactors at industrial scale.
That design choice is the whole point. A feeder-free, suspension process is the difference between a boutique therapy and a product. It is what lets HebeCell talk about "off-the-shelf" CAR-NK cells - cells engineered with a chimeric antigen receptor to home in on specific tumors - that could be deployed rapidly for any patient, rather than manufactured one painstaking batch at a time.
The target list is broad by design: cancer first, then autoimmune disease and viral infection. Each is a "pipeline" hanging off the same platform. HebeCell has been stacking partners to extend it - a strategic investment from Jacobio Pharmaceuticals in 2021, a gene-editing collaboration with Logomix in 2023, and a nanobody collaboration with Proteintech to give the cells new ways to recognize their targets.
Lu co-authored the peer-reviewed case for the approach - "CAR-NK Cells from Engineered Pluripotent Stem Cells: Off-the-shelf Therapeutics for all Patients" - in Stem Cells Translational Medicine. The title is the argument. The science is the proof.
Illustrative comparison based on HebeCell's stated feeder-free, single-use-bioreactor design.
Something new and never seen before in the NK therapeutic field.— John Lu, on HebeCell's 2023 gene-editing collaboration
Before he was a founder, Lu was the research lead inside one of regenerative medicine's most ambitious early companies. When that company got swallowed, he didn't slow down - he started over with a new platform in mind.
A biochemist who kept adding lenses - oncology, public health, cancer biology - until he could see a cell therapy from the molecule all the way out to the patient population.
Because the cells start from self-renewing pluripotent stem cells, the source never runs out. HebeCell's patented method produces allogeneic NK cells indefinitely - a sentence most cell therapy companies cannot write.
Donor-derived therapies are made per patient. Lu's bet is the opposite: one universal, standardized product, ready when the patient is, rather than a manufacturing project that starts after diagnosis.
"Hebe" is the Greek goddess of youth and renewal - a quiet wink for a company built on regenerative medicine. The science is dense; the branding is a classics joke.
The aim isn't a single drug. It's to make off-the-shelf immune cell therapies - iPSC-derived NK and CAR-NK cells - universal, affordable, and available to every patient by industrializing how they're made. If donor-derived therapy is a hand-built car, Lu is building the assembly line. See the work at hebecellcorp.com.